Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps investors identify effective metrics for assessing momentum in stocks [2] Group 2: Groupon (GRPN) Performance - Groupon currently holds a Momentum Style Score of A and a Zacks Rank of 2 (Buy), indicating strong potential for outperformance [3][4] - Over the past week, GRPN shares increased by 7.52%, significantly outperforming the Zacks Internet - Commerce industry, which rose by only 0.12% [6] - In the last quarter, GRPN shares surged by 102.77%, and over the past year, they gained 125.16%, while the S&P 500 only increased by 8.73% and 13.86%, respectively [7] Group 3: Trading Volume and Earnings Outlook - GRPN's average 20-day trading volume is 1,637,182 shares, indicating a bullish trend when combined with rising stock prices [8] - Recent earnings estimate revisions for GRPN show a positive trend, with three estimates moving higher for the full year, raising the consensus estimate from -$0.34 to $0.30 [10] - The positive earnings outlook and strong price performance contribute to GRPN's status as a 2 (Buy) stock with a Momentum Score of A [12]

Company Overview - ANIXA BIOSCIENCES INC currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance [4] Price Performance - Over the past week, ANIX shares increased by 1.2%, while the Zacks Medical - Biomedical and Genetics industry declined by 2.54% [6] - In the last month, ANIX shares rose by 30.32%, significantly outperforming the industry's 1.71% [6] - Over the past quarter, ANIX shares have risen by 19.93%, and over the last year, they are up 39.66%, compared to the S&P 500's increases of 5.86% and 12.83%, respectively [7] Trading Volume - ANIX's average 20-day trading volume is 245,662 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for ANIX has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$0.41 to -$0.38 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Given the strong price performance, positive earnings outlook, and high Momentum Style Score, ANIXA BIOSCIENCES INC is positioned as a promising investment opportunity [12]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Group 1: Momentum Style Score - CF Industries (CF) currently holds a Momentum Style Score of B, indicating a favorable momentum characteristic [2] - The Zacks Rank for CF is 2 (Buy), suggesting a strong potential for outperformance in the market [3] Group 2: Price Performance - Over the past week, CF shares increased by 0.43%, matching the performance of the Zacks Fertilizers industry [5] - In a longer timeframe, CF's monthly price change is 8.59%, significantly outperforming the industry's 2.68% [5] - CF shares have risen 23.52% over the past quarter and 27.68% over the last year, while the S&P 500 has only increased by 6.75% and 11.69%, respectively [6] Group 3: Trading Volume - CF's average 20-day trading volume is 3,284,338 shares, which serves as a bullish indicator when combined with rising stock prices [7] Group 4: Earnings Outlook - In the past two months, 6 earnings estimates for CF have been revised upwards, increasing the consensus estimate from $5.97 to $6.82 [9] - For the next fiscal year, 4 estimates have moved up while 2 have been revised down [9] Group 5: Conclusion - CF Industries is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a strong candidate for near-term investment [11]

Core Viewpoint - The article emphasizes the importance of a structured decision-making process when considering investments in popular stocks, highlighting three critical filters to apply before making investment decisions [2][3][8]. Group 1: Decision-Making Filters - The first filter is to confirm the consistency of decision-making logic, ensuring that the rationale for buying or selling a stock remains unchanged throughout the investment process [3][4]. - The second filter advises maintaining a cautious attitude towards the notion of "this time is different," especially in the context of popular stocks, as high valuations are likely during periods of market enthusiasm [6][7]. - The third filter focuses on confirming personal preparedness for investment, including emotional readiness and understanding the risk associated with high volatility in popular stocks [8]. Group 2: Market Context - The article notes that there are many strong stocks emerging in the market this year, particularly in sectors like robotics and new consumption [2]. - It highlights the common dilemma investors face regarding whether to invest in trending stocks, suggesting that this decision is subjective and varies from person to person [2]. Group 3: Emotional and Financial Preparedness - Investors are encouraged to assess their emotional and financial readiness before pursuing high-risk investments, as volatility can lead to irrational decision-making [8]. - The article underscores that the fear of missing out (FOMO) is a common emotional challenge in investing, but emphasizes that missing an opportunity does not equate to a financial loss [8].

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps investors identify effective metrics for assessing momentum in stocks [2] Group 2: Instil Bio, Inc. (TIL) Performance - Instil Bio, Inc. currently holds a Momentum Style Score of A and a Zacks Rank of 2 (Buy) [3][4] - TIL shares have increased by 4.07% over the past week, while the Zacks Medical - Biomedical and Genetics industry has decreased by 2.9% [6] - Over the past quarter, TIL shares have risen by 47.62%, and by 188.4% over the last year, significantly outperforming the S&P 500's gains of 5.72% and 10.37% respectively [7] Group 3: Trading Volume and Earnings Outlook - TIL's average 20-day trading volume is 429,110 shares, indicating a bullish sign with rising stock prices [8] - In the past two months, one earnings estimate for TIL has increased, raising the consensus estimate from -$8.30 to -$7.71 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive earnings outlook [10] Group 4: Conclusion - Considering the positive momentum indicators and earnings outlook, TIL is positioned as a promising stock for near-term gains [12]

Company Overview - Oric Pharmaceuticals, Inc. (ORIC) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance expectations [4] Performance Metrics - Over the past week, ORIC shares have increased by 14.08%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 5.43% [6] - In a longer time frame, ORIC's monthly price change is 104.01%, significantly higher than the industry's 7.54% [6] - Over the last quarter, ORIC shares have risen by 28.76%, and over the past year, they are up 25.91%, while the S&P 500 has only moved 8.33% and 12.92%, respectively [7] Trading Volume - ORIC's average 20-day trading volume is 1,988,020 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, 5 earnings estimates for ORIC have been revised upwards, while only 1 has been revised downwards, leading to an increase in the consensus estimate from -$2.06 to -$1.75 [10] - For the next fiscal year, 3 estimates have moved upwards, with 1 downward revision during the same period [10] Conclusion - Given the strong performance metrics and positive earnings outlook, ORIC is positioned as a promising investment opportunity with a Momentum Score of A [12]

Company Overview - Sagimet Biosciences Inc. (SGMT) currently holds a Momentum Style Score of B, indicating a favorable momentum outlook [3] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [4] Price Performance - SGMT shares have increased by 56.62% over the past week, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 5.43% during the same period [6] - Over the past month, SGMT's price change is 86.79%, compared to the industry's 8.65% [6] - In the last three months, SGMT shares have risen by 54.29%, and they are up 19.76% over the past year, while the S&P 500 has only moved 7.87% and 14.01%, respectively [7] Trading Volume - SGMT's average 20-day trading volume is 1,939,129 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, four earnings estimates for SGMT have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$3.68 to -$2.49 [10] - For the next fiscal year, three estimates have moved upwards, with one downward revision noted [10] Conclusion - Considering the positive momentum indicators and earnings outlook, SGMT is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [12]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell even higher, with the expectation that established trends will continue [1][2]. Company Overview: Grifols (GRFS) - Grifols currently holds a Momentum Style Score of A, indicating strong momentum potential [3]. - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4]. Performance Metrics - Over the past week, Grifols shares increased by 2.47%, while the Zacks Medical - Drugs industry remained flat [6]. - In a longer timeframe, Grifols' shares have risen by 15.44% over the past month, significantly outperforming the industry's 3.53% [6]. - For the past quarter, Grifols shares increased by 8.89%, and over the last year, they gained 15.12%, compared to the S&P 500's 3.59% and 14.21% respectively [7]. Trading Volume - Grifols has an average 20-day trading volume of 819,084 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the last two months, one earnings estimate for Grifols has increased, while none have decreased, raising the consensus estimate from $0.96 to $0.99 [10]. - For the next fiscal year, one estimate has also moved upwards with no downward revisions [10]. Conclusion - Given the strong performance metrics and positive earnings outlook, Grifols is recommended as a solid momentum pick for investors [11][12].

Company Overview - Delcath Systems, Inc. (DCTH) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance [4] Performance Metrics - DCTH shares have increased by 0.62% over the past week, outperforming the Zacks Medical - Instruments industry, which rose by 0.37% [6] - Over the past month, DCTH's price change is 37.2%, significantly higher than the industry's 1.13% [6] - In the last quarter, DCTH shares have risen by 36.27%, and over the past year, they have gained 149.3%, while the S&P 500 has only moved 2.37% and 14.4%, respectively [7] Trading Volume - The average 20-day trading volume for DCTH is 588,239 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for DCTH has increased, while none have decreased, raising the consensus estimate from $0.28 to $0.29 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Given the strong performance metrics and positive earnings outlook, DCTH is positioned as a promising momentum pick for investors [12]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Catalyst Pharmaceutical (CPRX) - Catalyst Pharmaceutical currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance in the market [3] Price Performance - CPRX shares have increased by 1.92% over the past week, while the Zacks Medical - Drugs industry remained flat [5] - Over the past month, CPRX's price change is 8.02%, outperforming the industry's 3.76% [5] - In the last quarter, shares of CPRX have risen by 18.84%, and over the past year, they have gained 55.3%, compared to the S&P 500's increases of 2.37% and 14.4%, respectively [6] Trading Volume - The average 20-day trading volume for CPRX is 1,094,588 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, four earnings estimates for CPRX have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from $2.15 to $2.25 [9] - For the next fiscal year, three estimates have moved up, while one has been revised down [9] Conclusion - Considering the strong momentum indicators and positive earnings outlook, CPRX is identified as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [11]